Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Tumble 12.2% in October: Crecon Report
December 8, 2016
- Mitsubishi Tanabe Fending Off Inroads from Biosimilars through Add’l Indications for Remicade
December 8, 2016
- Heike Prinz to Become 1st Female President of Bayer Yakuhin
December 7, 2016
- Acquisition of Long-Listed Drugs to Promote Generic Sales; Sales Target of 50 Billion Yen “in Range”: Kyowa Pharm
December 7, 2016
- Chugai to Enter Hemophilia Field with Emicizumab; Peak Sales Could Top 200 Billion Yen
December 6, 2016
- Kaketsuken Wraps Up Blanket Re-Inspection, Says There’s No Quality or Safety Concern
December 6, 2016
- GSK Won’t Invest in Aspen Japan
December 6, 2016
- Toyama Chemical Begins Japan PIII for Macrolide Antibiotic
December 6, 2016
- AZ Japan to Shed 40 Primary Care Jobs Via Voluntary Redundancy
December 6, 2016
- Novartis Files Tafinlar-Mekinist Combo for NSCLC
December 6, 2016
- Daiichi Sankyo’s HER2-Targeting ADC Gets Fast-Track Status in US
December 5, 2016
- Takeda, Lightstone Ventures Set Up Neuroscience R&D Firm
December 5, 2016
- Shionogi’s Sakigake-Designated Flu Drug Delivers Add’l Favorable PII Data
December 5, 2016
- Annual Price Revision Could Plunge Pharma Industry into Doldrums: Pfizer Japan Chief
December 5, 2016
- FDA Accepts sNDA for Abilify Maintena’s Bipolar I Disorder Indication
December 2, 2016
- Novartis Seeks Aplastic Anemia Indication for Revolade, Neoral
December 2, 2016
- Takeda to Build Dengue Vaccine Plant in Germany
December 2, 2016
- JACE for Giant Congenital Melanocytic Nevus Covered by Health Insurance: J-TEC
December 2, 2016
- Pfizer Japan Completes Transfer of Generics from Hospira Japan
December 2, 2016
- Oncolys Licenses Oncolytic Virus Telomelysin to Hengrui in China
December 2, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…